Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEA-CD70 + azacitidine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
SEA-CD70 + azacitidine is an investigational combination therapy for myeloid malignancies, specifically higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML). SEA-CD70 (PF-08046040) is a humanized, nonfucosylated, CD70-directed IgG1 monoclonal antibody with enhanced effector function, developed to target CD70, which is expressed on myeloid blasts. Azacitidine is a hypomethylating agent that increases CD70 expression, potentially augmenting the activity of SEA-CD70. Preclinical data and early-phase clinical trials show that the combination is well tolerated, with manageable adverse events and preliminary clinical efficacy in patients with untreated HR-MDS. The combination is being evaluated in multi-part, dose-finding and expansion studies, with plans for Phase III development in HR-MDS.
- Other names
- SEA-CD70 + AZA
02
Targets
CD70 (Cluster of Differentiation 70)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on SEA-CD70 + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEA-CD70 + azacitidine.